KVUE · Kenvue Inc
Price
Snapshot
50 fields · last close| Market Cap | $36.32B |
| P/E | 21.91 |
| Float | 1.92B |
| Beta | 0.45 |
| Volatility | 11.1% |
| Exchange | NYSE |
| Sector | Consumer products |
| Cap tier | Large cap |
| Macro sensitivity | Low |
| Clavix score | 81.2 |
| Price | 18.81 |
| Change | −0.53% |
| Prev Close | 18.91 |
| Open | 18.74 |
| Day Low | 18.71 |
| Day High | 18.95 |
| Avg Vol | 22 |
| Avg $ Vol | $411.8M |
| 52W High | 20.13 |
| 52W Low | 14.02 |
| 52W Pos | 78.4% |
| From High | −6.56% |
| From Low | +34.17% |
| Max DD 1Y | −13.26% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +5.79% |
| SMA 50 | +2.58% |
| SMA 200 | +4.08% |
| RSI (14) | 67.9 |
| Vol 30D | 21.3% |
| Vol 90D | 21.5% |
| 1Y Range | 14–20 |
| Daily bars | 536 |
| Perf Week | +6.84% |
| Perf Month | +5.82% |
| Perf Quarter | −0.58% |
| Perf Half Y | +7.38% |
| Perf Year | +16.30% |
| Perf YTD | +8.60% |
| Prev Day | −0.53% |
| Clavix | A- |
| Debt / Eq | 0.71 |
| Curr Ratio | 0.96 |
| Int Cover | 6.3× |
| FCF Margin | 11.4% |
| Rev Growth | −2.1% |
| Profit | Profitable |
| Leverage | Moderate |
| Sector rank | 4 / 17 |
What KVUE does
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women’s health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements.
It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee’s Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson’s, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson’s Baby, Johnson’s Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands.
Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
Clavix risk grade
regraded every trading dayKVUE grades A-, 81.2 of 100. Steadiest on Price Stability (69), most exposed on Sector Resilience (59, mixed). 3 of the 4 weighted dimensions sit above the Consumer products median. Ranks 4 of 17 in Consumer products by Clavix score.
How rough the ride is
| KVUE | Consumer products median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.45 | 1.22 |
| Volatilityannualized | 11.1% | 30.4% |
| Max drawdown, past yearworst peak-to-trough fall | −13.3% | — |
| Typical daily movemedian absolute daily change | 0.81% | — |
| Days beyond ±3%of the last 252 sessions | 12 (5%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| KVUE | Consumer products median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.45 | 1.22 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | High 56% of 18 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Consumer products names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| KVUE | |
|---|---|
| 1 week | +6.8% |
| 1 month | +5.8% |
| Year to date | +8.6% |
| 1 year | +16.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| KVUE | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 7 Sep |
| Average score0 most bearish, 100 most bullish | 62 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 2 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 2 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 18 Consumer products names Clavix covers; the tick is the sector median.
Growth
| KVUE | |
|---|---|
| Revenue growthyear over year | −2.1% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Consumer products median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openKimberly-Clark got enough Kenvue bondholders to agree to changes to their bond contracts during the early participation window, with over 90% of several bond series consenting (including 98.37% of bonds maturing in 2053). The changes do not become final until the closing timeline of Kimberly-Clark's pending acquisition of Kenvue is met.
Kimberly-Clark announced that enough Kenvue noteholders agreed to change the terms governing Kenvue's outstanding notes, clearing a required step in offers that let holders swap up to $7 billion of Kenvue notes for new Kimberly-Clark notes plus cash.
Kimberly-Clark received enough bondholder consents to amend the terms of Kenvue's outstanding notes as part of exchange offers worth up to $7 billion.
A portfolio manager says they are buying shares of Kenvue, the consumer health company behind brands found in most American medicine cabinets, as a way to invest outside the handful of tech stocks currently driving the market. No specific company news, earnings, or business update from Kenvue is reported in the article.
Kimberly-Clark is acquiring Kenvue in a deal that pays KVUE shareholders $3.50 in cash plus 0.14625 KMB shares per share, with a target close in the fourth quarter. Jim Cramer endorsed KMB as a buy, calling the combination with Kenvue 'unstoppable' and citing roughly $2.1 billion in projected annual synergies. Kimberly-Clark is currently working to clear EU regulatory hurdles for the deal.
Nearest peers by size
Consumer products| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| KMB | Kimberly-Clark Corp | B+ | $35.11B | 17.96 | 0.29 | Compare |
| EL | Estee Lauder Companies Inc | B- | $37.88B | 208.12 | 1.25 | Compare |
| DHI | D.R. Horton Inc | B | $38.99B | 12.77 | 1.39 | Compare |
| SN | Sharkninja Inc | B | $26.27B | 37.79 | 1.23 | Compare |
| CHD | Church & Dwight Co Inc | A- | $24.79B | 33.29 | 0.47 | Compare |
| GRMN | Garmin Ltd | B | $54.92B | 29.26 | 0.91 | Compare |
| PHM | Pultegroup Inc | B | $21.29B | 11.16 | 1.20 | Compare |
| LEN | Lennar Corp | B | $18.31B | 14.00 | 1.41 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.